{"type":"trials","record":{"id":41452,"source_id":"clinicaltrials-gov","external_id":"NCT07069647","title":"Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","brief_summary":"Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are leading causes of vision loss, with rising incidence due to aging populations and increasing diabetes prevalence. However, delayed diagnoses are common due to low disease literacy and lack of dedicated screening tools in internal medicine. This multi-center RCT at National Taiwan University Hospital evaluates the clinical effectiveness and cost-effectiveness of the VeriSee AI-assisted diagnostic software for DR and AMD screening. Participants include adults with diabetes and individuals aged 50 and above meeting AMD screening criteria, randomized to AI-assisted screening with immediate physician explanation or standard physician-only screening. Primary outcomes include detection rates of DR and AMD, ophthalmology referral outcomes, and patient/physician satisfaction. Data collection will occur from April 2025 to December 2027. This study aims to provide evidence on the clinical utility of AI-assisted ophthalmic screening in improving early detection, facilitating timely treatment, and reducing severe visual impairment and healthcare burdens in real-world clinical settings.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"National Taiwan University Hospital","enrollment":4300,"countries":["Taiwan"],"start_date":"2025-10-02","completion_date":"2027-12-31","last_update_date":"2026-07-22","source_url":"https://clinicaltrials.gov/study/NCT07069647","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"20 Years","comparator":"Standard Physician Screening","organization":"National Taiwan University Hospital","interventions":["VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration","Standard fundus photography with physician interpretation"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The proportion of confirmed cases requiring injection or laser treatment — From screening to physician-confirmed diagno…","The proportion of screened positive cases requiring treatment, where treatment improves prognosis — From screening to p…"],"design_description":"RANDOMIZED · PARALLEL · SCREENING · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration (AMD)","Diabetic Retinopathy (DR)","VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration","Standard fundus photography with physician interpretation"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07069647","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-10-02 to 2027-12-31","comparator":"Standard Physician Screening","confidence":"structured-source","population":"ALL · 20 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.815Z","intervention":["VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration","Standard fundus photography with physician interpretation"],"participants":4300,"study_design":"RANDOMIZED · PARALLEL · SCREENING · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The proportion of confirmed cases requiring injection or laser treatment — From screening to physician-confirmed diagno…","The proportion of screened positive cases requiring treatment, where treatment improves prognosis — From screening to p…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related, geriatric.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41452","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}